Amicus Therapeutics, Inc. (LON:0HF9)
London
· Delayed Price · Currency is GBP · Price in USD 6.26
-0.04 (-0.65%)
At close: Jun 4, 2025
Amicus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 543.14 | 528.3 | 399.36 | 329.23 | 305.51 | 260.89 | Upgrade
|
| Revenue Growth (YoY) | 28.25% | 32.29% | 21.30% | 7.76% | 17.11% | 43.16% | Upgrade
|
| Cost of Revenue | 51.07 | 52.94 | 37.33 | 38.6 | 34.47 | 31.04 | Upgrade
|
| Gross Profit | 492.07 | 475.35 | 362.03 | 290.63 | 271.05 | 229.84 | Upgrade
|
| Selling, General & Admin | 327.18 | 323.38 | 275.27 | 213.04 | 192.71 | 156.41 | Upgrade
|
| Research & Development | 108.87 | 109.36 | 152.38 | 276.68 | 272.05 | 308.44 | Upgrade
|
| Operating Expenses | 444.28 | 441.29 | 435.52 | 495.06 | 470.97 | 473.7 | Upgrade
|
| Operating Income | 47.79 | 34.06 | -73.49 | -204.43 | -199.92 | -243.85 | Upgrade
|
| Interest Expense | -48.62 | -49.6 | -50.15 | -37.12 | -32.47 | -22.43 | Upgrade
|
| Interest & Investment Income | 4.68 | 5.41 | 7.08 | 3.02 | 0.51 | 3.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.48 | -9.44 | -15.89 | 4.18 | -2.9 | -0.78 | Upgrade
|
| EBT Excluding Unusual Items | -0.08 | -19.57 | -132.45 | -234.35 | -234.78 | -263.83 | Upgrade
|
| Merger & Restructuring Charges | -3.14 | -9.19 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -1.13 | -6.62 | - | - | Upgrade
|
| Other Unusual Items | - | - | -16.52 | -1.08 | -6.77 | -10.42 | Upgrade
|
| Pretax Income | -3.22 | -28.76 | -150.1 | -242.04 | -241.55 | -274.25 | Upgrade
|
| Income Tax Expense | 26.16 | 27.35 | 1.48 | -5.47 | 8.91 | 2.6 | Upgrade
|
| Net Income | -29.37 | -56.11 | -151.58 | -236.57 | -250.46 | -276.85 | Upgrade
|
| Net Income to Common | -29.37 | -56.11 | -151.58 | -236.57 | -250.46 | -276.85 | Upgrade
|
| Shares Outstanding (Basic) | 306 | 304 | 295 | 289 | 271 | 259 | Upgrade
|
| Shares Outstanding (Diluted) | 306 | 304 | 295 | 289 | 271 | 259 | Upgrade
|
| Shares Change (YoY) | 2.52% | 3.12% | 2.11% | 6.50% | 4.85% | 7.67% | Upgrade
|
| EPS (Basic) | -0.10 | -0.18 | -0.51 | -0.82 | -0.92 | -1.07 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.18 | -0.51 | -0.82 | -0.92 | -1.07 | Upgrade
|
| Free Cash Flow | 1.61 | -37.44 | -76.53 | -170.34 | -206.38 | -236.52 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | -0.12 | -0.26 | -0.59 | -0.76 | -0.91 | Upgrade
|
| Gross Margin | 90.60% | 89.98% | 90.65% | 88.28% | 88.72% | 88.10% | Upgrade
|
| Operating Margin | 8.80% | 6.45% | -18.40% | -62.09% | -65.44% | -93.47% | Upgrade
|
| Profit Margin | -5.41% | -10.62% | -37.96% | -71.85% | -81.98% | -106.12% | Upgrade
|
| Free Cash Flow Margin | 0.30% | -7.09% | -19.16% | -51.74% | -67.55% | -90.66% | Upgrade
|
| EBITDA | 56.02 | 42.61 | -65.62 | -199.08 | -193.71 | -235.01 | Upgrade
|
| EBITDA Margin | 10.31% | 8.07% | -16.43% | -60.47% | -63.41% | -90.08% | Upgrade
|
| D&A For EBITDA | 8.23 | 8.55 | 7.87 | 5.34 | 6.21 | 8.85 | Upgrade
|
| EBIT | 47.79 | 34.06 | -73.49 | -204.43 | -199.92 | -243.85 | Upgrade
|
| EBIT Margin | 8.80% | 6.45% | -18.40% | -62.09% | -65.44% | -93.47% | Upgrade
|
Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.